In contrast, the overexpression of VASH1 did not significantly affect sensitivity to CDDP, another key chemotherapeutic agent for ovarian cancer, possibly because CDDP targets DNA itself, not microtubules. This evidence concerns the gene VASH1 and ovarian carcinoma.